Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROP2-CAR/ IL15 TGFBR2 KO Engineered Cord Blood-Derived NK Cells In Patients With Diffused Or Multifocal Oral Premalignant Lesions
NCT07631013Phase 1Not yet recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TROP2 CAR/IL-15 TGFBR2 KO NK cells in Oral Precancerous Lesions, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and Adverse Events at 1 year. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
TROP2 CAR/IL-15 TGFBR2 KO NK cells
03
Conditions
Oral Precancerous Lesions
Beyond the preview
Go deeper on NCT07631013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07631013.